Effect of different dialysis modalities on serum hepcidin, the key regulator of iron metabolism

Not Applicable

Completed

• Conditions: Chronic kidney disease; Urological and Genital Diseases

• Registration Number: ISRCTN15957905
• Lead Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Brief Summary

1. 2017 results in https://www.ncbi.nlm.nih.gov/pubmed/28353202 (added 30/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2015-01-10
• Study Start: 2015-10-12
• Last Update Posted: 3 February 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

1. Aged over 18 years.
2. Chronic hemodialysys patients on erytrhopoiesis-stimulating agents
3. Have been attending the unit for dialysis for more than 3 months by June 2009
4. Have participated in the previous study (protocol # 1460)

Exclusion Criteria

1. Liver cirrhosis
2. Neoplasia
3. Chronic Inflammatory disorder
4. Acute inflammatory disease
5. Solid organ transplantation
6. No informed consent to trial # 1460

Study & Design

• Study Type: Interventional
• Study Design: Not specified